Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.37 |
| ▸ | EDNRB | P24530 | 2/20 | 0.36 |
| ▸ | EDNRA | P25101 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087195 | 0.90 | KMT2A (0.42) | CTSDTP53 | |
| SCHEMBL7084905 | 0.83 | DAO (0.39) | CTSDTP53 | |
| SCHEMBL7084329 | 0.81 | L3MBTL1 (0.43) | CTSDTP53 | |
| SCHEMBL6752250 | 0.78 | MAPT (0.39) | MMP3EDNRBEDNRAALOX5APFEN1 | |
| SCHEMBL7072844 | 0.78 | LTB4R2 (0.40) | MMP3EDNRBEDNRA | |
| SCHEMBL7096610 | 0.78 | PDE4A (0.42) | EDNRBEDNRAALOX5APFEN1TP53 | |
| SCHEMBL7087253 | 0.78 | MMP3 (0.39) | MMP3EDNRBEDNRAALOX5APFEN1 | |
| SCHEMBL7098737 | 0.76 | LMNA (0.40) | MMP3EDNRAALOX5APFEN1TP53 | |
| SCHEMBL6749825 | 0.76 | HPGDS (0.41) | ALOX5APFEN1CTSDTP53 | |
| SCHEMBL7087252 | 0.76 | TP53 (0.36) | EDNRATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | F11, F12, F13A1 | MMP3 934/4885USP30 2776/4885EDNRB 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.